Identification

Name
Suvorexant
Accession Number
DB09034
Type
Small Molecule
Groups
Approved
Description

Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.

Structure
Thumb
Synonyms
  • [(7R)-4-(5-Chlor-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanon
  • [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
  • [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-méthyl-1,4-diazépan-1-yl][5-méthyl-2-(2H-1,2,3-triazol-2-yl)phényl]méthanone
  • [(7R)-4-(5-chlorobenzoxazol-2-yl)-7-methylhexahydro-1H-1,4-diazepin-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone
External IDs
MFCD18251525 / MK 4305 / MK-4305 / MK4305
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
BelsomraTablet, film coated5 mg/1OralMerck Sharp & Dohme Limited2014-08-29Not applicableUs
BelsomraTablet, film coated15 mg/1OralMerck Sharp & Dohme Limited2014-08-29Not applicableUs
BelsomraTablet, film coated10 mg/1OralMerck Sharp & Dohme Limited2014-08-29Not applicableUs
BelsomraTablet, film coated20 mg/1OralMerck Sharp & Dohme Limited2014-08-29Not applicableUs
Categories
UNII
081L192FO9
CAS number
1030377-33-3
Weight
Average: 450.93
Monoisotopic: 450.1571017
Chemical Formula
C23H23ClN6O2
InChI Key
JYTNQNCOQXFQPK-MRXNPFEDSA-N
InChI
InChI=1S/C23H23ClN6O2/c1-15-3-5-20(30-25-8-9-26-30)18(13-15)22(31)29-12-11-28(10-7-16(29)2)23-27-19-14-17(24)4-6-21(19)32-23/h3-6,8-9,13-14,16H,7,10-12H2,1-2H3/t16-/m1/s1
IUPAC Name
5-chloro-2-[(5R)-5-methyl-4-[5-methyl-2-(2H-1,2,3-triazol-2-yl)benzoyl]-1,4-diazepan-1-yl]-1,3-benzoxazole
SMILES
[H][[email protected]@]1(C)CCN(CCN1C(=O)C1=C(C=CC(C)=C1)N1N=CC=N1)C1=NC2=C(O1)C=CC(Cl)=C2

Pharmacology

Indication

Suvorexant is indicated for the treatment of insomnia characterized by difficulties with sleep onset and/or sleep maintenance.

Structured Indications
Pharmacodynamics
Not Available
Mechanism of action

Suvorexant is a dual antagonist of orexin receptors OX1R and OX2R. It exerts its pharmacological effect by inhibiting binding of neuropeptides orexin A and B, also known as hypocretin 1 and 2, that are produced by neurons in the lateral hypothalamus. These neurons control the wake-promoting centers of the brain and are active during wakefulness, especially during motor activities, and stop firing during sleep. By inhibiting the reinforcement of arousal systems, suvorexant use causes a decrease in arousal and wakefulness, rather than having a direct sleep-promoting effect.

TargetActionsOrganism
AOrexin receptor type 1
antagonist
Human
AOrexin receptor type 2
antagonist
Human
Absorption

Peak concentrations occur at a median Tmax of 2 hours under fasted conditions. Ingestion of suvorexant with a high-fat meal has no effect on AUC or Cmax, but may delay Tmax by approximately 1.5 hours. Mean absolute bioavailability of 10 mg is 82%.

Volume of distribution

Mean volume of distribution is approximately 49 litres.

Protein binding

Suvorexant is extensively bound (>99%) to human plasma proteins and does not preferentially distribute into red blood cells. It binds to both human serum albumin and alpha1-acid glycoprotein.

Metabolism

Suvorexant is primarily metabolized by cytochrome-P450 3A4 enzyme (CYP3A4) with a minor contribution from CYP2C19. Major circulating metabolites are suvorexant and a hydroxy-suvorexant metabolite, which is not expected to be pharmacologically active. There is potential for drug-drug interactions with drugs that inhibit or induce CYP3A4 activity.

Route of elimination

Approximately 66% is eliminated in feces and 23% is eliminated in urine.

Half life

Mean half life is approximately 12 hours.

Clearance
Not Available
Toxicity

Dose-related somnolence and CNS depression are the most common adverse effects associated with the use of suvorexant. It has also been shown to impair driving skills and may increase the risk of falling asleep while driving. Next-day impairments are found to be highest if suvorexant is taken with less than a full night of sleep remaining, with higher doses, or if co-administered with other CNS depressants or CYP3A inhibitors. Complex behaviours such as sleep driving, preparing and eating food, and making phone calls have been reported in association with the use of hypnotics such as suvorexant. A dose-dependant increase in suicidal ideation has been observed, especially in patients with a previous diagnosis of depression. Sleep paralysis, hypnagogic/hypnopompic hallucinations including vivid and disturbing perceptions, and mild cataplexy have also been reported. There are no adequate studies in pregnant women to ensure its safety during pregnancy or breast feeding.

Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
7-Nitroindazole7-Nitroindazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
AcepromazineAcepromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
AceprometazineAceprometazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
AdipiplonAdipiplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
AgomelatineAgomelatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
AlaproclateThe risk or severity of adverse effects can be increased when Suvorexant is combined with Alaproclate.Experimental
AlfaxaloneAlfaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
AlfentanilAlfentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
AllopregnanoloneAllopregnanolone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
AlphacetylmethadolAlphacetylmethadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
AlphaprodineAlphaprodine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit
AlprazolamAlprazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
AmiodaroneThe serum concentration of Suvorexant can be increased when it is combined with Amiodarone.Approved, Investigational
AmisulprideAmisulpride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
AmitriptylineAmitriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
AmobarbitalAmobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
AmoxapineAmoxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
AmperozideAmperozide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
AprepitantThe serum concentration of Suvorexant can be increased when it is combined with Aprepitant.Approved, Investigational
AripiprazoleAripiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
ArticaineArticaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
AsenapineAsenapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
AtazanavirThe serum concentration of Suvorexant can be increased when it is combined with Atazanavir.Approved, Investigational
AtomoxetineThe serum concentration of Suvorexant can be increased when it is combined with Atomoxetine.Approved
AzaperoneAzaperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational, Vet Approved
AzelastineAzelastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BaclofenBaclofen may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BarbitalBarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit
BenperidolBenperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
BenzocaineBenzocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Benzyl alcoholBenzyl alcohol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BoceprevirThe serum concentration of Suvorexant can be increased when it is combined with Boceprevir.Approved, Withdrawn
BortezomibThe serum concentration of Suvorexant can be increased when it is combined with Bortezomib.Approved, Investigational
BrexpiprazoleBrexpiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BromazepamBromazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
BromisovalBromisoval may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
BromperidolBromperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
BrompheniramineBrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
BrotizolamBrotizolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Withdrawn
BupivacaineBupivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
BuprenorphineBuprenorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational, Vet Approved
BuspironeBuspirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
ButabarbitalButabarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ButacaineButacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
ButalbitalButalbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ButambenButamben may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ButethalButethal may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ButorphanolButorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Vet Approved
CanertinibCanertinib may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
CarbamazepineCarbamazepine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
CarbinoxamineCarbinoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CarfentanilCarfentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit, Investigational, Vet Approved
CarisoprodolCarisoprodol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CeritinibThe serum concentration of Suvorexant can be increased when it is combined with Ceritinib.Approved
CetirizineCetirizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Chloral hydrateChloral hydrate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Vet Approved
ChlordiazepoxideChlordiazepoxide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ChlormezanoneChlormezanone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Withdrawn
ChloroprocaineChloroprocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ChlorphenamineChlorphenamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ChlorpromazineChlorpromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
ChlorprothixeneChlorprothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Withdrawn
ChlorzoxazoneChlorzoxazone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CinchocaineCinchocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
CitalopramThe risk or severity of adverse effects can be increased when Suvorexant is combined with Citalopram.Approved
ClarithromycinThe serum concentration of Suvorexant can be increased when it is combined with Clarithromycin.Approved
ClemastineClemastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ClidiniumClidinium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ClobazamClobazam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
clomethiazoleclomethiazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
ClomipramineClomipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
ClonazepamClonazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ClonidineClonidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ClopenthixolClopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
ClorazepateClorazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ClothiapineClothiapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
ClotrimazoleThe serum concentration of Suvorexant can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CobicistatThe serum concentration of Suvorexant can be increased when it is combined with Cobicistat.Approved
CocaineCocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
CodeineCodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
ConivaptanThe serum concentration of Suvorexant can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibThe serum concentration of Suvorexant can be increased when it is combined with Crizotinib.Approved
CyclizineCyclizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CyclobenzaprineCyclobenzaprine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
CyclosporineThe serum concentration of Suvorexant can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineCyproheptadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DantroleneDantrolene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DapiprazoleDapiprazole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Dapoxetine.Investigational
DarunavirThe serum concentration of Suvorexant can be increased when it is combined with Darunavir.Approved
DelavirdineThe serum concentration of Suvorexant can be increased when it is combined with Delavirdine.Approved
DeramciclaneDeramciclane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
DesfluraneDesflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DesipramineDesipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DesloratadineDesloratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Desvenlafaxine.Approved
DetomidineDetomidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
DexbrompheniramineDexbrompheniramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DexmedetomidineDexmedetomidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
DextromoramideDextromoramide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
DextropropoxypheneDextropropoxyphene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational, Withdrawn
DezocineDezocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
DiazepamDiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Vet Approved
Diethyl etherDiethyl ether may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
DifenoxinDifenoxin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
DihydrocodeineDihydrocodeine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
DihydroergotamineThe serum concentration of Suvorexant can be increased when it is combined with Dihydroergotamine.Approved
DihydroetorphineDihydroetorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
DihydromorphineDihydromorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
DiltiazemThe serum concentration of Suvorexant can be increased when it is combined with Diltiazem.Approved
DimenhydrinateDimenhydrinate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DiphenhydramineDiphenhydramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DiphenoxylateDiphenoxylate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
DixyrazineDixyrazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
DoramectinDoramectin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
DoxepinDoxepin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
DoxycyclineThe serum concentration of Suvorexant can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
DPDPEDPDPE may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
DronedaroneThe serum concentration of Suvorexant can be increased when it is combined with Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
DrotebanolDrotebanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Duloxetine.Approved
DyclonineDyclonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EcgonineEcgonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Illicit
EcopipamEcopipam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
EfavirenzEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
EltanoloneEltanolone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
EnfluraneEnflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Vet Approved
EntacaponeEntacapone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
EnzalutamideThe serum concentration of Suvorexant can be decreased when it is combined with Enzalutamide.Approved
ErythromycinThe serum concentration of Suvorexant can be increased when it is combined with Erythromycin.Approved, Vet Approved
EscitalopramThe risk or severity of adverse effects can be increased when Suvorexant is combined with Escitalopram.Approved, Investigational
EstazolamEstazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
EszopicloneEszopiclone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EthanolEthanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EthchlorvynolEthchlorvynol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Withdrawn
EthosuximideEthosuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EthotoinEthotoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Ethyl carbamateEthyl carbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Withdrawn
Ethyl chlorideEthyl chloride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental, Investigational
Ethyl loflazepateEthyl loflazepate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
EthylmorphineEthylmorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
EtidocaineEtidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EtifoxineEtifoxine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational, Withdrawn
EtizolamEtizolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EtomidateEtomidate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Suvorexant is combined with Etoperidone.Withdrawn
EtorphineEtorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit, Vet Approved
EzogabineEzogabine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FelbamateFelbamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FencamfamineFencamfamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Withdrawn
FentanylFentanyl may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational, Vet Approved
FexofenadineFexofenadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FlibanserinFlibanserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FluanisoneFluanisone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
FluconazoleThe serum concentration of Suvorexant can be increased when it is combined with Fluconazole.Approved
FludiazepamFludiazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
FlumazenilFlumazenil may decrease the sedative activities of Suvorexant.Approved
FlunarizineFlunarizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FlunitrazepamFlunitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
FluoxetineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Fluoxetine.Approved, Vet Approved
FlupentixolFlupentixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Withdrawn
FluphenazineFluphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FlurazepamFlurazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
FluspirileneFluspirilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Fluticasone propionateFluticasone propionate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FluvoxamineFluvoxamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
FosamprenavirThe serum concentration of Suvorexant can be increased when it is combined with Fosamprenavir.Approved
FosphenytoinFosphenytoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
FospropofolFospropofol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
GabapentinGabapentin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Gabapentin EnacarbilGabapentin Enacarbil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Gamma Hydroxybutyric AcidGamma Hydroxybutyric Acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
GepironeGepirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
GlutethimideGlutethimide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
GuanfacineGuanfacine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
HalazepamHalazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Withdrawn
HaloperidolHaloperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
HalothaneHalothane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
HeroinHeroin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
HexobarbitalHexobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
HydrocodoneSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneHydromorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
IdelalisibThe serum concentration of Suvorexant can be increased when it is combined with Idelalisib.Approved
IloperidoneIloperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ImatinibThe serum concentration of Suvorexant can be increased when it is combined with Imatinib.Approved
ImipramineImipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
IndalpineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Indalpine.Investigational, Withdrawn
IndinavirThe serum concentration of Suvorexant can be increased when it is combined with Indinavir.Approved
IndiplonIndiplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
IsavuconazoniumThe serum concentration of Suvorexant can be increased when it is combined with Isavuconazonium.Approved, Investigational
IsofluraneIsoflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
IsradipineThe serum concentration of Suvorexant can be increased when it is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Suvorexant can be increased when it is combined with Itraconazole.Approved, Investigational
KetamineKetamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
KetazolamKetazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
KetobemidoneKetobemidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
KetoconazoleThe serum concentration of Suvorexant can be increased when it is combined with Ketoconazole.Approved, Investigational
LamotrigineLamotrigine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
LevetiracetamLevetiracetam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
LevobupivacaineLevobupivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
LevocabastineLevocabastine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LevocetirizineLevocetirizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LevodopaLevodopa may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Levomethadyl AcetateLevomethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
LevomilnacipranThe risk or severity of adverse effects can be increased when Suvorexant is combined with Levomilnacipran.Approved
LevorphanolLevorphanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LidocaineLidocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
LithiumLithium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LofentanilLofentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit
LopinavirThe serum concentration of Suvorexant can be increased when it is combined with Lopinavir.Approved
LoprazolamLoprazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
LoratadineLoratadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LorazepamLorazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LormetazepamLormetazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LovastatinThe serum concentration of Suvorexant can be increased when it is combined with Lovastatin.Approved, Investigational
LoxapineLoxapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
LuliconazoleThe serum concentration of Suvorexant can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Suvorexant can be decreased when it is combined with Lumacaftor.Approved
LurasidoneLurasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
MaprotilineMaprotiline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MebicarMebicar may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
MeclizineMeclizine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MedazepamMedazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
MedetomidineMedetomidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
MelatoninMelatonin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Nutraceutical, Vet Approved
MelperoneMelperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
MepivacaineMepivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
MeprobamateMeprobamate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
MeptazinolMeptazinol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
MesoridazineMesoridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
MetaxaloneMetaxalone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MethadoneMethadone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Methadyl AcetateMethadyl Acetate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
MethapyrileneMethapyrilene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Withdrawn
MethaqualoneMethaqualone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Illicit, Withdrawn
MethocarbamolMethocarbamol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
MethohexitalMethohexital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MethotrimeprazineSuvorexant may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneMethoxyflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Vet Approved
MethsuximideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MethylecgonineMethylecgonine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
MethylphenobarbitalMethylphenobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MetyrosineSuvorexant may increase the sedative activities of Metyrosine.Approved
MidazolamMidazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
MifepristoneThe serum concentration of Suvorexant can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Suvorexant is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
MirtazapineMirtazapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MitotaneThe serum concentration of Suvorexant can be decreased when it is combined with Mitotane.Approved
MolindoneMolindone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
MorphineMorphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
NalbuphineNalbuphine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
NefazodoneThe serum concentration of Suvorexant can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Suvorexant can be increased when it is combined with Nelfinavir.Approved
NetupitantThe serum concentration of Suvorexant can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Suvorexant can be increased when it is combined with Nevirapine.Approved
NilotinibThe serum concentration of Suvorexant can be increased when it is combined with Nilotinib.Approved, Investigational
NitrazepamNitrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Nitrous oxideNitrous oxide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
NorfluraneNorflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
NormethadoneNormethadone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
NortriptylineNortriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OlanzapineOlanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
OlaparibThe serum concentration of Suvorexant can be increased when it is combined with Olaparib.Approved
OlopatadineOlopatadine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OndansetronOndansetron may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OpiumOpium may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
OrphenadrineOrphenadrine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OsanetantOsanetant may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
OxazepamOxazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OxethazaineOxethazaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
OxprenololOxprenolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OxybuprocaineOxybuprocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
OxycodoneOxycodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
OxymorphoneOxymorphone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Vet Approved
PaliperidonePaliperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ParaldehydeParaldehyde may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
ParoxetineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Paroxetine.Approved, Investigational
PenfluridolPenfluridol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
PentazocinePentazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PentobarbitalPentobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PerazinePerazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
PerospironePerospirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PerphenazinePerphenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PethidinePethidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PhenazocinePhenazocine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
PhenibutPhenibut may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
PhenobarbitalPhenobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PhenoperidinePhenoperidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
PhenoxyethanolPhenoxyethanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PhenytoinPhenytoin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PimozidePimozide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PipamperonePipamperone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
PipotiazinePipotiazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
PiritramidePiritramide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
PizotifenPizotifen may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PomalidomidePomalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PosaconazoleThe serum concentration of Suvorexant can be increased when it is combined with Posaconazole.Approved, Investigational, Vet Approved
PramipexoleSuvorexant may increase the sedative activities of Pramipexole.Approved, Investigational
PramocainePramocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PrazepamPrazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
PregabalinPregabalin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
PrilocainePrilocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PrimidonePrimidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
ProcaineProcaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Vet Approved
ProchlorperazineProchlorperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PromazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PromethazinePromethazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
PropanididPropanidid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
ProparacaineProparacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
PropofolPropofol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Vet Approved
PropoxycainePropoxycaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ProtriptylineProtriptyline may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ProxibarbalProxibarbal may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
PSD502PSD502 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
QuazepamQuazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit
QuetiapineQuetiapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
QuinisocaineQuinisocaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
RacloprideRaclopride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
RamelteonRamelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
RanolazineThe serum concentration of Suvorexant can be increased when it is combined with Ranolazine.Approved, Investigational
RemifentanilRemifentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
RemoxiprideRemoxipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Withdrawn
ReserpineReserpine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
RifabutinThe serum concentration of Suvorexant can be decreased when it is combined with Rifabutin.Approved
RifampicinThe serum concentration of Suvorexant can be decreased when it is combined with Rifampicin.Approved
RifapentineThe serum concentration of Suvorexant can be decreased when it is combined with Rifapentine.Approved
RisperidoneRisperidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
RitanserinRitanserin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
RomifidineRomifidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
RopiniroleSuvorexant may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineRopivacaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
RotigotineSuvorexant may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Suvorexant.Approved
SaquinavirThe serum concentration of Suvorexant can be increased when it is combined with Saquinavir.Approved, Investigational
ScopolamineScopolamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SecobarbitalSecobarbital may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
SepranoloneSepranolone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
SertindoleSertindole may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Withdrawn
SertralineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Sertraline.Approved
SevofluraneSevoflurane may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
SildenafilThe serum concentration of Suvorexant can be increased when it is combined with Sildenafil.Approved, Investigational
SimeprevirThe serum concentration of Suvorexant can be increased when it is combined with Simeprevir.Approved
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
St. John's WortThe serum concentration of Suvorexant can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolStiripentol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
SufentanilSufentanil may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SulfisoxazoleThe serum concentration of Suvorexant can be increased when it is combined with Sulfisoxazole.Approved, Vet Approved
SulpirideSulpiride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
SultoprideSultopride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
TandospironeTandospirone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TasimelteonTasimelteon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TelaprevirThe serum concentration of Suvorexant can be increased when it is combined with Telaprevir.Approved, Withdrawn
TelithromycinThe serum concentration of Suvorexant can be increased when it is combined with Telithromycin.Approved
TemazepamTemazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TetrabenazineTetrabenazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TetracaineTetracaine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
TetrahydropalmatineTetrahydropalmatine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
TetrodotoxinTetrodotoxin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Investigational
ThalidomideThalidomide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational, Withdrawn
ThiamylalThiamylal may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
ThiopentalThiopental may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
ThioridazineThioridazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Withdrawn
ThiothixeneThiothixene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TiagabineTiagabine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TiaprideTiapride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TiclopidineThe serum concentration of Suvorexant can be increased when it is combined with Ticlopidine.Approved
TiletamineTiletamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
TilidineTilidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
TizanidineTizanidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TolcaponeTolcapone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Withdrawn
TopiramateTopiramate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TramadolTramadol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
TranylcypromineTranylcypromine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TrazodoneTrazodone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TriazolamTriazolam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Tricaine methanesulfonateTricaine methanesulfonate may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
TrichloroethyleneTrichloroethylene may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TrifluoperazineTrifluoperazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TrifluperidolTrifluperidol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
TriflupromazineTriflupromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Vet Approved
TrimipramineTrimipramine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
TriprolidineTriprolidine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Valproic AcidValproic Acid may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
VenlafaxineThe serum concentration of Suvorexant can be increased when it is combined with Venlafaxine.Approved
VeraliprideVeralipride may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
VerapamilThe serum concentration of Suvorexant can be increased when it is combined with Verapamil.Approved
VigabatrinVigabatrin may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Vinyl etherVinyl ether may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
VoriconazoleThe serum concentration of Suvorexant can be increased when it is combined with Voriconazole.Approved, Investigational
VortioxetineVortioxetine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
XenonXenon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Experimental
XylazineXylazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
ZaleplonZaleplon may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Illicit, Investigational
ZiconotideZiconotide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Suvorexant is combined with Zimelidine.Withdrawn
ZiprasidoneZiprasidone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ZolazepamZolazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Vet Approved
ZolpidemZolpidem may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ZonisamideZonisamide may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
ZopicloneZopiclone may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
ZotepineZotepine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
ZuclopenthixolZuclopenthixol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
Food Interactions
  • Grapefruit Juice

References

General References
  1. Palasz A, Lapray D, Peyron C, Rojczyk-Golebiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R: Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol. 2014 Jan;17(1):157-68. doi: 10.1017/S1461145713000552. Epub 2013 May 23. [PubMed:23702225]
  2. Patel KV, Aspesi AV, Evoy KE: Suvorexant: a dual orexin receptor antagonist for the treatment of sleep onset and sleep maintenance insomnia. Ann Pharmacother. 2015 Apr;49(4):477-83. doi: 10.1177/1060028015570467. Epub 2015 Feb 9. [PubMed:25667197]
  3. Reddy A, Puvvada SC, Kommisetti S, El-Mallakh RS, Lippmann S: Suvorexant: something new for sleep? Acta Neuropsychiatr. 2015 Feb;27(1):53-5. doi: 10.1017/neu.2014.31. Epub 2014 Nov 14. [PubMed:25397996]
  4. Michelson D, Snyder E, Paradis E, Chengan-Liu M, Snavely DB, Hutzelmann J, Walsh JK, Krystal AD, Benca RM, Cohn M, Lines C, Roth T, Herring WJ: Safety and efficacy of suvorexant during 1-year treatment of insomnia with subsequent abrupt treatment discontinuation: a phase 3 randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2014 May;13(5):461-71. doi: 10.1016/S1474-4422(14)70053-5. Epub 2014 Mar 27. [PubMed:24680372]
  5. Howland RH: Suvorexant: a novel therapy for the treatment of insomnia. J Psychosoc Nurs Ment Health Serv. 2014 Oct;52(10):23-6. doi: 10.3928/02793695-20140924-01. [PubMed:25291725]
External Links
KEGG Drug
D10082
PubChem Compound
24965990
PubChem Substance
310264985
ChemSpider
24662178
BindingDB
50318701
ChEBI
82698
ChEMBL
CHEMBL1083659
HET
SUV
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Suvorexant
PDB Entries
4s0v / 4zj8
FDA label
Download (403 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingBasic SciencePanic Disorders1
1CompletedTreatmentHepatic Insufficiency / Sleeplessness1
1CompletedTreatmentSleep Apnea Syndrome1
1CompletedTreatmentSleeplessness3
1RecruitingTreatmentInsomnia Disorders1
2CompletedTreatmentPrimary Insomnia1
2RecruitingTreatmentCocaine Use Disorders / Feeling Anxious1
3CompletedTreatmentPrimary Insomnia2
3CompletedTreatmentSleeplessness1
3RecruitingTreatmentAlzheimer's Disease (AD) / Sleeplessness1
4Not Yet RecruitingTreatmentDepression / Major Depressive Disorder (MDD) / Sleeplessness1
4Not Yet RecruitingTreatmentSleeplessness1
4RecruitingTreatmentBipolar Disorder (BD) / Sleeplessness1
4RecruitingTreatmentFibromyalgia / Sleeplessness1
4RecruitingTreatmentHigh Blood Pressure (Hypertension) / Sleeplessness1
4RecruitingTreatmentPosttraumatic Stress Disorders1
4RecruitingTreatmentPosttraumatic Stress Disorders / Sleeplessness1
4RecruitingTreatmentSleep Disorder, Shift-Work1
4RecruitingTreatmentSleeplessness2
Not AvailableRecruitingOtherAmyloid-beta1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral5 mg/1
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US20110195957No2011-04-192031-04-19Us
US7951797No2009-11-202029-11-20Us

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.117 mg/mLALOGPS
logP3.86ALOGPS
logP4.04ChemAxon
logS-3.6ALOGPS
pKa (Strongest Basic)0.25ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area80.29 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity134.36 m3·mol-1ChemAxon
Polarizability46.68 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as n,n-dialkyl-m-toluamides. These are aromatic that contain a m-toluamide, where the carboxamide group is N- substituted with two alkyl chains.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Toluenes
Direct Parent
N,N-dialkyl-m-toluamides
Alternative Parents
Phenyl-1,2,3-triazoles / Benzamides / Benzoxazoles / Dialkylarylamines / Benzoyl derivatives / 1,4-diazepanes / Aryl chlorides / Tertiary carboxylic acid amides / Oxazoles / Heteroaromatic compounds
show 7 more
Substituents
N,n-dialkyl-m-toluamide / Phenyltriazole / Phenyl-1,2,3-triazole / Benzamide / Benzoic acid or derivatives / Benzoxazole / Benzoyl / Dialkylarylamine / 1,4-diazepane / Diazepane
show 23 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
1,3-benzoxazoles, organochlorine compound, aromatic amide, triazoles, diazepine (CHEBI:82698)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Peptide hormone binding
Specific Function
Moderately selective excitatory receptor for orexin-A and, with a lower affinity, for orexin-B neuropeptide. Seems to be exclusively coupled to the G(q) subclass of heteromeric G proteins, which ac...
Gene Name
HCRTR1
Uniprot ID
O43613
Uniprot Name
Orexin receptor type 1
Molecular Weight
47535.33 Da
References
  1. Palasz A, Lapray D, Peyron C, Rojczyk-Golebiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R: Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol. 2014 Jan;17(1):157-68. doi: 10.1017/S1461145713000552. Epub 2013 May 23. [PubMed:23702225]
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Peptide hormone binding
Specific Function
Nonselective, high-affinity receptor for both orexin-A and orexin-B neuropeptides.
Gene Name
HCRTR2
Uniprot ID
O43614
Uniprot Name
Orexin receptor type 2
Molecular Weight
50693.965 Da
References
  1. Palasz A, Lapray D, Peyron C, Rojczyk-Golebiewska E, Skowronek R, Markowski G, Czajkowska B, Krzystanek M, Wiaderkiewicz R: Dual orexin receptor antagonists - promising agents in the treatment of sleep disorders. Int J Neuropsychopharmacol. 2014 Jan;17(1):157-68. doi: 10.1017/S1461145713000552. Epub 2013 May 23. [PubMed:23702225]

Drug created on February 23, 2015 15:11 / Updated on December 01, 2017 16:12